OSA in Primary Care
Obstructive Sleep Apnea: Recognition, Treatment, and Adherence in the Primary Care Setting
Program Overview
The National Institutes of Health report that approximately 18 million Americans (20% of the U.S. adult population) suffer from obstructive sleep apnea (OSA). Despite the prevalence of this common condition, studies show that 90% of people with OSA remain undiagnosed. Patients who suffer silently with undiagnosed OSA face significant quality of life and associated health issues. Identifying patients with OSA can be a challenge in the busy primary care office setting and requires the clinician to maintain a high level of suspicion based on a variety of risk factors, physical findings, and sometimes-subtle patient complaints. Once diagnosed and treatment is initiated, successful management, including consistent follow-up and monitoring of patient adherence, is the cornerstone to better patient outcomes. This educational activity will provide primary care clinicians with evidence-based science and the management skills necessary to make significant improvements in the lives of their patients with OSA.
Learning Objectives
After completing this activity, the participant should be better able to
- Recognize the signs and symptoms of OSA and be able to employ simple assessment questions to identify the possibility of OSA
- Identify various treatment modalities for patients with OSA including implementation of CPAP and bilevel PAP equipment
- Employ strategies for assessment of OSA treatment to improve patient adherence and effectiveness including resolution of residual symptoms
Accreditation/Designation Statement
Primary Care Network is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Primary Care Network designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
For information on the eligibility of this continuing education credit toward meeting your CME/CE requirements, please consult your professional association or state licensing board.
Target Audience: This activity is targeted to all physicians and other healthcare professionals who treat patients with sleep disorders.
Release Date: February 28, 2011
Expiration Date: February 28, 2012
Medium: Online CME (slides/audio)
Acknowledgment of Commercial Support
This activity was developed from the live Best Practices in Primary Care™ program held in Anaheim, California, on November 16, 2010, and is funded by Cephalon, Inc., Philips Respironics, and ResMed.
Method of Participation
To receive CME credit for this activity, participant must read the CME information (including the learning objectives and disclosures) and review the entire activity (slides and audio ). After finishing the activity, participant must complete the post-test, evaluation, and all required personal information. To receive CME certificate participant will need to pass the post-test with 70% accuracy or better.
Post-test and Evaluation
After completing this activity, participant should click on the Post-test button at the end of the activity. If participant receives less than 70% on the post-test, participant should return to the beginning of the activity to review the activity again. After successful completion of the post-test, participant will be asked to fill out an evaluation form and prompted to print the CME certificate. Participant should PLEASE be ready to print certificate at this time.
Statement of Disclosure and Independence
It is the policy of Primary Care Network (PCN) to ensure all its sponsored educational activities are planned, developed, and conducted in accordance with the ACCME’s Essential Areas and Policies. In accordance with ACCME requirements, PCN has Conflict of Interest and Disclosure Policies that are designed to ensure that PCN sponsored educational activities are fair balanced, independent, evidence-based, and based on scientific rigor.
Primary Care Network’s Resolution of Personal Conflicts of Interest (COI) Policy aims to ensure that all conflicts are resolved prior to the activity, content is developed and presented free of commercial bias, and is in the interest of promoting improvements or quality in healthcare. All individuals who are in a position to influence and/or control content of a PCN sponsored activity are required to disclose to the participants any real or apparent conflict of interest related to the activity. The educational content is also reviewed for independence and content validation by an independent external clinical reviewer and internal clinical reviewer. Independence is also monitored through the activity and overall program evaluation process.
The opinions, ideas, recommendations, and perspectives expressed in the accompanying presentations in this Primary Care Education activity are those of the activity authors and presenting faculty only and do not necessarily reflect the opinions, ideas, recommendations, or perspectives of their affiliated institutions, Primary Care Network, Primary Care Education, Advisory Boards and Consultants, or the activity’s commercial supporters.
Faculty and Disclosures
Paul P. Doghramji, MD, FAAFP
Family Physician
Collegeville Family Practice
Medical Director of Health Services
Ursinus College
Collegeville, Pennsylvania
Dr. Doghramji serves on the speakers’ bureaus for AstraZeneca, Cephalon, Pfizer, and Takeda, and on the advisory boards for Cephalon, Pfizer, Sepracor, and URL Pharma. He also serves as a consultant for Cephalon, Pfizer, and URL Pharma and is a stock shareholder of Pfizer.
Brian Koffman, MDCM
Clinical Professor
Department of Family Medicine
Keck School of Medicine
USC Family Practice
St. Jude Heritage Medical Group
Diamond Bar, California
Dr. Koffman serves on the speaker’s bureau for Takeda.
Planning Committee and Disclosures
Paul P. Doghramji, MD, FAAFP
Family Physician
Collegeville Family Practice
Medical Director of Health Services
Ursinus College
Collegeville, Pennsylvania
Dr. Doghramji serves on the speakers’ bureaus for AstraZeneca, Cephalon, Pfizer, and Takeda, and on the advisory boards for Cephalon, Pfizer, Sepracor, and URL Pharma. He also serves as a consultant for Cephalon, Pfizer, and URL Pharma and is also a stock shareholder of Pfizer.
Brian Koffman, MDCM
Clinical Professor
Department of Family Medicine
Keck School of Medicine
USC Family Practice
St. Jude Heritage Medical Group
Diamond Bar, California
Dr. Koffman serves on the speaker’s bureau for Takeda.
Michael J. Thorpy, MD
Professor of Neurology
Albert Einstein College of Medicine
Bronx, New York
Dr. Thorpy serves on the speaker’s bureau and is a consultant for Cephalon.
Review Committee Disclosure
In accordance with PCN policy, all content is reviewed by external independent peer reviewers for balance, objectivity, and commercial bias. The peer reviewers, staff, and other individuals who control content have no relevant financial relationships to disclose.
Unlabeled Use Declaration
During their presentation(s), faculty may discuss an unlabeled use or an investigational use not approved for a commercial product. Each faculty member is required to disclose this information to the audience when referring to an unlabeled or investigational use.
This activity has expired and is no longer available for CME; however, we hope you still enjoy the education.
If you are using a mobile device, this activity may not view properly.
Attachments
Generic to Brand Name Drug Table
I need my CME certificate but the post test does not pop up…
Ms. Nida,
First, if you can let me know what exactly the message is stating when you try to access the post-test, then I will better be able to help you. Second, you have to be sure you have gone through the entire activity before you can access the post-test. And third, there are a few locations that have firewalls up that will not allow access to our post-tests. Now, I know you have taken our post-test before, so if you are on a different computer, try using the same computer as you have used before when you have successfully passed the other post-tests; then we know that is not the problem. But again, please feel free to email me the language you are being given when you try to access the post-test if you have done the other three items and are still not able to successfully reach the post-test and we'll get you through this together. Thank you.